Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Hemophagocytic syndrome (HPS), also known as hemophagocytic lymphohistiocytosis (HLH), is an
immune mediated life-threatening disease. There is no uniform recommendation for salvage
treatment of HLH. Based on the results of current clinical trials, the marketing situation of
the drug in China, and the use requirements of pegylated recombinant human granulocyte
stimulating factor(PEG-rhG-CSF), this study was conducted in patients who received the DEP
rescue therapy or dexamethasone combined with VP-16 maintenance therapy. The aim of this
study was to evaluate the efficacy and safety of PEG-rhG-CSF(Jinyouli®) for the recovery of
neutropenia after chemotherapy in patients with hemophagocytic syndrome.